Core Viewpoint - Phreesia (PHR) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending January 2025, Phreesia is expected to earn -$1.10 per share, representing a 56.2% change from the previous year's reported figure, with a 10.2% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of Phreesia to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Technical Analysis - Phreesia Inc (PHR) has reached a key technical support level with its 50-day simple moving average crossing above its 200-day simple moving average, forming a "golden cross" [1] - A golden cross is a bullish technical chart pattern indicating potential upward momentum, typically involving the 50-day and 200-day moving averages [2] - The golden cross pattern consists of three stages: a downtrend bottoming out, a crossover of moving averages triggering a positive trend reversal, and continued upward momentum [3] Recent Performance - PHR has gained 11.8% over the past four weeks [4] - The company currently holds a 3 (Hold) rating on the Zacks Rank, suggesting potential for a breakout [4] Earnings Outlook - PHR has a positive earnings outlook with no earnings estimate cuts for the current quarter and 5 upward revisions in the past 60 days [4] - The Zacks Consensus Estimate for PHR has increased [4] Investment Consideration - Investors may consider PHR for potential gains due to its technical indicators and positive earnings estimate revisions [5]

Core Viewpoint - Phreesia (PHR) has shown a significant price increase of 25.5% over the past four weeks, with a mean price target of $29.80 indicating a potential upside of 25% from the current price of $23.84 [1] Group 1: Price Target Insights - The consensus price target is often viewed with skepticism due to analysts' tendency to set overly optimistic targets, which may mislead investors [2][8] - A tight clustering of price targets, indicated by a low standard deviation of $3.30, suggests strong agreement among analysts regarding the stock's price movement [6] - The lowest price estimate is $23, indicating a potential decline of 3.5%, while the highest estimate suggests a 51% increase to $36 [6] Group 2: Earnings Estimates and Analyst Sentiment - The Zacks Consensus Estimate for the current year has increased by 8.6%, reflecting positive sentiment among analysts with no negative revisions [4] - Analysts' growing optimism regarding PHR's earnings prospects is supported by strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - PHR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [12]

Company Overview - Phreesia (NYSE: PHR) provides software solutions for healthcare providers, focusing on registration, scheduling, payments, and clinical support [1] - The software enhances patient intake processes and improves overall patient experiences [1] Recent Performance - Prior to the Q3 2024 earnings report, Phreesia's stock price increased by 21.0% [1] Analyst Background - Dr. Duru, who has been blogging about financial markets since 2000, has extensive experience through various market cycles, including the dot-com bubble, financial crisis, and the coronavirus pandemic [1] - Dr. Duru's blog "One-Twenty Two" offers unique perspectives on financial markets, covering a range of topics including stocks, options, currencies, and Bitcoin [1] - The blog utilizes both technical and fundamental analysis for trading and investing strategies [1]

Phreesia (PHR) shares ended the last trading session 13.9% higher at $21.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.9% loss over the past four weeks.Phreesia scored a strong price increase, driven by investors’ optimism surrounding its impending fiscal 2025 third-quarter results, slated to be released on Dec. 9 after the closing bell. In the fiscal second quarter, Phreesia reached a crucial milestone by ...

Maskot Summary Following my coverage on Phreesia, Inc. (NYSE:PHR) in Jun'24, in which I recommended a buy rating due to my expectation that the business has no issues growing revenue at 20% given that client growth is still strong, this post is to provide an update on my thoughts on the business and stock. I remain buy-rated for PHR as the growth outlook remains solid. New logo adds remain on track to hit FY25 targets, and the increase in transaction size in the current pipeline lends credence to PHR's next ...

Phreesia (PHR) reported $102.12 million in revenue for the quarter ended July 2024, representing a year-overyear increase of 19%. EPS of -$0.31 for the same period compares to -$0.68 a year ago. The reported revenue represents a surprise of +0.35% over the Zacks Consensus Estimate of $101.76 million. With the consensus EPS estimate being -$0.37, the EPS surprise was +16.22%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

Company Overview - Phreesia is a leading provider of comprehensive solutions that transform the healthcare experience by activating patients in their care[4] - The company empowers healthcare organizations to maximize efficiency, drive growth, and deliver great care with tools that transcend patient intake[4] - Phreesia serves more than 4,100 AHSCs (Average Healthcare Services Clients)[4,10] - The company facilitated over 150 million patient visits in Fiscal Year 2024[4] Financial Performance - Total revenue for the latest twelve months was $390 million[4] - The company experienced 22% total revenue growth in the latest 12 months[4] - Q2 Fiscal Year 2025 total revenue reached $102.1 million, a 19% year-over-year increase[21] - Adjusted EBITDA for Q2 Fiscal Year 2025 was $6.5 million[13,21] - The company processed over $4 billion in patient payments in the latest twelve months[4] Market Opportunity - Phreesia operates in a total addressable market (TAM) of approximately $10 billion[16] - The company estimates $95 billion addressable out-of-pocket spend in the United States[15] Future Outlook - The company projects FY2025 total revenue to be between $416 million and $426 million, representing a 17%-20% year-over-year growth[26] - Phreesia anticipates approximately 4,200 AHSCs by the end of FY2025[26] - The company expects approximately 4,500 AHSCs in FY2026[26]

Phreesia (PHR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.22%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.51 per share when it actually produced a loss of $0.35, delivering a surprise of 31.37%. Over the last four quarters, the ...

Wall Street analysts expect Phreesia (PHR) to post quarterly loss of $0.37 per share in its upcoming report, which indicates a year-over-year increase of 45.6%. Revenues are expected to be $102.05 million, up 18.9% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Prior to a company's earnings announcement, it is crucial to co ...